01/01/1987 - "In this 12-week study acifran provided safe and effective treatment for Type IIa hyperlipoproteinemia."
09/01/1985 - "The hypolipidemic effects of acifran were evaluated in a randomized, double-blind, placebo-controlled study of 30 patients with type IIa hyperlipoproteinemia. "
09/01/1985 - "Controlled trial of acifran in type II hyperlipoproteinemia."
|2.||Renal Insufficiency (Renal Failure)
01/01/1990 - "Renal failure substantially reduced the plasma and renal clearance of total and particularly of unbound acifran, moderately reduced its volume of distribution, and increased its elimination half-life from 1.4 to 1.7 hours to 5.7 hours. "
01/01/1990 - "Pharmacokinetics and disposition of the lipid-lowering drug acifran in normal subjects and in patients with renal failure."
|3.||Chronic Kidney Failure (Chronic Renal Failure)
|1.||Blood Proteins (Serum Proteins)